Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.

Veldhuis JD, Evans WS, Bowers CY

The Journal of clinical endocrinology and metabolism1 Feb 2002Cited by 31 (Europe PMC)

PMID11836333DOI10.1210/jcem.87.2.8251PepBankPUB-11836333

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy postmenopausal women, combined GHRH and GHRP‑2 infusion elevated mean 24-h serum GH concentration on placebo.
In plain wordsIn healthy postmenopausal women on placebo, a combined GHRH and GHRP‑2 infusion raised average 24-hour growth hormone levels.
Peptide
GHRP-2
Outcome
IncreaseMean 24-h serum GH during GHRH plus GHRP-2 infusion
Study
n = 7
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean 24-h serum GH
8.1 microg/liter
placebo
Source sentences
Summary
Double peptidyl secretagogue stimulation elevated mean 24-h serum GH concentrations to 8.1 +/- 1.0 microg/liter (placebo)
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633301
02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy postmenopausal women receiving combined GHRH and GHRP‑2 infusion, estradiol did not change mean 24-h serum GH concentration compared with placebo.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change average 24-hour growth hormone compared with placebo.
Peptide
GHRP-2
Outcome
No significant changeMean 24-h serum GH with estradiol during GHRH plus GHRP-2 infusion
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean 24-h serum GH
8.1 microg/liter
placebo
Mean 24-h serum GH
7.7 microg/liter
estradiol
Source sentences
Summary
Double peptidyl secretagogue stimulation elevated mean 24-h serum GH concentrations to 8.1 +/- 1.0 microg/liter (placebo) and 7.7 +/- 0.89 microg/liter (E2; P = NS) and evoked prominently pulsatile patterns of GH secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633302
03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, estradiol did not change GH secretory burst amplitude compared with placebo.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change the size of growth hormone bursts.
Peptide
GHRP-2
Outcome
No significant changeGH secretory burst amplitude with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GH secretory burst amplitudes of 0.62 +/- 0.93 (placebo) and 0.72 +/- 0.16 (E2) microg/liter x min
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633303
04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, estradiol did not change GH pulse frequency compared with placebo.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change how often growth hormone pulses occurred.
Peptide
GHRP-2
Outcome
No significant changeGH pulse frequency with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GH pulse frequencies of 27 +/- 1.8 (placebo) and 23 +/- 1.9 (E2) events/24 h
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633304
05HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, estradiol did not change GH half-life compared with placebo.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change how long growth hormone lasted in the blood.
Peptide
GHRP-2
Outcome
No significant changeGH half-life with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GH half-lives of 12 +/- 0.74 (placebo) and 15 +/- 4.5 (E2) min
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633305
06HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, estradiol did not change basal (nonpulsatile) GH secretion compared with placebo.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change steady background growth hormone release.
Peptide
GHRP-2
Outcome
No significant changeBasal GH secretion with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
basal (nonpulsatile) GH secretion 70 +/- 22 (placebo) and 57 +/- 18 (E2) ng/liter x min
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633306
07HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, the approximate entropy of serial GH release was invariant of estradiol supplementation.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change the regularity of growth hormone release.
Peptide
GHRP-2
Outcome
No significant changeApproximate entropy of serial GH release with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The approximate entropy (ApEn) of serial GH release [1.297 +/- 0.061 (placebo) and 1.323 +/- 0.06 (E2)]
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633307
08HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 infusion, the mesor, amplitude and acrophase of 24-h rhythmic GH secretion were invariant of estradiol supplementation.
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol did not change the daily rhythm of growth hormone release.
Peptide
GHRP-2
Outcome
No significant change24-h rhythmic GH secretion with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
and the mesor (cosine mean), amplitude, and acrophase (time of the maximum) of 24-h rhythmic GH secretion were likewise invariant of estrogen supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633308
09HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
During combined GHRH and GHRP‑2 stimulation, estradiol replacement disrupted the serial regularity of pulsatile GH output (elevated the ApEn ratio).
In plain wordsIn postmenopausal women receiving GHRH plus GHRP‑2, estradiol made the sequence of growth hormone pulse sizes less orderly.
Peptide
GHRP-2
Outcome
IncreaseSerial regularity of GH burst mass with estradiol
Study
n = 7
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In contrast, ApEn analysis of the evolution of successive GH secretory burst-mass values over 24 h disclosed that E2 replacement disrupts the serial regularity of pulsatile GH output (elevates the ApEn ratio) during combined GHRH/GHRP-2 stimulation (P = 0.004).
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, seven healthy postmenopausal women underwent frequent (10-min) blood sampling for 24 h during simultaneous i.v. infusion of GHRH and GHRP-2 each at a rate of 1 microg/kg x h on d 10 of randomly ordered placebo or 17beta-estradiol (E2) (1 mg orally twice daily) replacement.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1183633309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.